A Phase I/II Clinical Study of Chimeric Antigen Receptor T-cell Therapy Targeting CD19 and BCMA (GC012F) in Patients With Relapsed/Refractory Multiple Myeloma.

This document provides information on a Phase I/II clinical study being conducted in China to evaluate the effectiveness and safety of a chimeric antigen receptor T-cell therapy called GC012F in patients with relapsed/refractory multiple myeloma. The study is open to both male and female participants aged 18-75 who have received at least three prior lines of therapy and meet specific laboratory and organ function requirements. Eligible subjects will receive a single dose of GC012F infusion after lymphodepletion. The study is currently recruiting and is expected to be completed by June 2026. [Extracted from the article]